COMPANY NEWS
ANIVIA Announces Participation in the “New Southbound Medical Collaboration and Industrial Development Project”
August 14-18 Taipei, Taiwan
ANIVIA is proud to announce its participation in the “New Southbound Medical Collaboration and Industrial Development Project,” featuring the “2024 Life for VAD International Symposium.” At this event, ANIVIA’s product development team showcased our state-of-the-art ISO 13485 certified manufacturing facility alongside our cutting-edge extracorporeal technology, including the Anivia SG1000 pump console. This engagement underscores our commitment to advancing healthcare through innovation and fostering collaboration across Southeast Asia.
ANIVIA Unveils Neuroprotection Technology at BIO Asia Taiwan 2024
July 26-29, 2024 –Taipei, Taiwan
ANIVIA is thrilled to announce our participation in BIO Asia Taiwan 2024, where we presented our groundbreaking technology for selective hypothermia. Our state-of-the-art innovations captivated numerous attendees.
At the event, we showcased the development of our extracorporeal system for cerebral selective brain hypothermia. In addition, we introduced our open system console for cardiopulmonary applications, marking a significant advancement in cardiovascular care.
We are excited to bring this new dimension in medical treatment to the forefront and eagerly anticipate sharing more about our future developments. Stay tuned for more exciting updates!
APMTD Global Limited Rebrands to ANIVIA Medical Holdings, Unveiling New Era in Healthcare Innovation
June 21, 2024 Taipei, Taiwan
APMTD Global Limited (APMTD), a pioneer in the medical device industry, proudly announces its rebranding to ANIVIA Medical Holdings. This name change is part of a global brand transformation. The group name and logo will be updated as well. The transition will be officially completed in June 2024.
The rebranding initiative reflects ANIVIA Medical Holdings’ mission to fulfill unmet healthcare needs in cardiovascular diseases. The concept aligns with our goal to minimize brain damage and preserve patients’ quality of life.
“ANIVIA embodies our commitment to improving patient outcomes in cardiovascular diseases through our patented extracorporeal technology,” said Henry Lin, co-founder and CEO of ANIVIA Medical Holdings. “Our goal is not only to save patients’ lives but also to improve their prognosis, echoing our slogan: ‘More than Just Life Support, We Restore What Life is Meant To Be,’” he added.
Stay informed of ANIVIA Medical Holdings’ groundbreaking advancements and connect with us through our website: www.aniviamed.com
About ANIVIA Medical Holdings
ANIVIA Medical Holdings is at the forefront of medical device innovation. The company has already brought to market a unique open-system extracorporeal console and is endeavoring to introduce a more advanced system for cerebral selective hypothermia. ANIVIA Medical Holdings has established itself as a pioneer in ICU extracorporeal solutions.
Anivia Ignites Sales at the 2024 AmSect Conference in USA
March 20-24, 2024
Anivia marked a pivotal moment at the 62nd American Society of Extracorporeal Technology (AmSect) Conference, the premier gathering for perfusionists worldwide. We seized this opportunity to deepen our connections with customers and conducted comprehensive training sessions for our U.S. distribution partners, demonstrating our commitment to excellence and leadership in extracorporeal technology.
APMTD won the golden prize in H. Spectrum Project Phoenix
October 18, 2023
APMTD won the golden prize at H Spectrum Demo Day and was awarded an MOU for business collaboration with Foxconn Technology Co. Ltd. H Spectrum, a leading health tech international accelerator in APAC, hosts the Golden Phoenix competition every year. In 2023, 183 companies registered for the Project Phoenix competition, and 13 companies advanced to the final round. APMTD secured the golden prize in the international group.
Anivia Attracts Spotlight at the 42nd Cardiothoracic Symposium
September 13-16, 2023
APMTD proudly showcased our innovations at the 42nd Cardiothoracic Surgery Symposium in San Diego, USA. Spanning four days, this prestigious international conference attracts perfusionists from around the globe. We were thrilled by the enthusiastic reception from attendees and have identified numerous potential clients.
APMTD Unveils Anivia Console at Sanibel Symposium 2023
May 10-13, 2023
APMTD Unveils Anivia Console at Sanibel Symposium 2023 held in Bonita Springs, Florida from May 10-13, 2023. The Anivia Console is the first “open-system” extracorporeal platform developed to meet the growing clinical demands for flexibility in the medical field. The system was cleared by the FDA in February 2023.
APMTD Secures U.S. FDA 510(k) Clearance for Anivia SG-1000 Console
February 3rd, 2023
APMTD has been granted 510(k) premarket notification for its Anivia SG-1000 console, enabling the company to market the product in the United States. The Anivia SG-1000 console is a pioneering open-system extracorporeal console, setting a new industry standard.
APMTD Showcases Innovative Solutions at the 33rd Annual ELSO Conference
September 15-17, 2022
APMTD attended the 33rd Annual ELSO Conference in Boston, USA, where our open platform and unique capabilities attracted significant interest from 46 groups in the ECMO field. Many visitors appreciated the open platform’s flexibility and compatibility with various disposables. Our ability to support two different pump drives on one bedside cart was also well-received.
For more information, please contact us.